France

Inventiva Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Inventiva Announces the Decision by the Investigator to Reduce the Number of Patients in the Ongoing Phase II Trial Evaluating lanifibranor ...

Lead Product(s): Lanifibranor

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: IVA 337

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

Following higher than expected effects on steatosis reduction during the Phase IIb NATIVE trial in NASH, the number of patients to be recruited in the trial evaluating lanifibranor in patients with T2DM and NAFLD has been reduced to 34 (vs. 64 initially).

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Poxel Announces Positive Pharmacokinetic (PK) / (PD) Study Results for PXL770

Lead Product(s): PXL770

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL770

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

The study met its key objectives; PXL770 was observed to demonstrate a consistent PK profile in the likely-NASH patient population and was observed to be safe and well-tolerated .

Inventiva Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Inventiva’s Lanifibranor Meets Primary & Key Secondary Endpoints in the Phase IIb NATIVE Clinical Trial In Non-Alcoholic Steatohepatitis

Lead Product(s): Lanifibranor

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

Lanifibranor met the primary endpoint in the ITT population at the dose of 1200mg/day with a statistically significant (p = 0.004) decrease of at least two points in the SAF activity score6, compared to baseline, with no worsening of fibrosis.

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

Lead Product(s): PXL770

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

PXL770 treatment was observed to improve cardio-renal disease and adrenoleukodystrophy (ALD) /adrenomyeloneuropathy (AMN) in animal models.

Poxel

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Poxel Successfully Raises €17.7 Million in a Capital Increase

Lead Product(s): PXL770

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: JMP Securities LLC

Deal Size: $19.4 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 25, 2020

Details:

The use of proceeds will enable the Company to accelerate the development plans for PXL770 and PXL065 for the treatment of NASH, to pursue development activities in other metabolic diseases and for general corporate purposes.